Literature DB >> 29417233

Non-profit Drug Research and Development at a Crossroads.

Szymon Jarosławski1, Mondher Toumi2, Pascal Auquier1, Claude Dussart3,4.   

Abstract

In wealthy nations, non-profit drug R&D has been proposed to reduce the prices of medicines. We sought to review the ethical and economic issues concerning non-profit drug R&D companies, and the possible impact that their pricing strategy may have on the innovation efforts from for-profit companies targeting the same segment of the pharmaceutical market. There are two possible approaches to pricing drugs developed by non-profit R&D programs: pricing that maximises profits and "affordable" pricing that reflects the cost of manufacturing and distribution, plus a margin that ensures sustainability of the drug supply. Overall, the non-profits face ethical challenges - due to the lack of resources, they are unable to independently commercialize their products on a large scale; however, the antitrust law does not permit them to impose prices on potential licensees. Also, reduced prices for the innovative products may result in drying the for-profit R&D in the area.

Keywords:  biotechnology; drug industry; non-profit drug development; orphan drugs; rare diseases

Mesh:

Year:  2018        PMID: 29417233     DOI: 10.1007/s11095-018-2351-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Continuum of overlapping clones spanning the entire human chromosome 21q.

Authors:  I Chumakov; P Rigault; S Guillou; P Ougen; A Billaut; G Guasconi; P Gervy; I LeGall; P Soularue; L Grinas
Journal:  Nature       Date:  1992-10-01       Impact factor: 49.962

2.  Neglected diseases fund touted.

Authors:  Declan Butler
Journal:  Nature       Date:  2010-05-20       Impact factor: 49.962

3.  Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.

Authors:  Victoria G Hale; Katherine Woo; Helene Levens Lipton
Journal:  Health Aff (Millwood)       Date:  2005 Jul-Aug       Impact factor: 6.301

4.  Fixing the price of the orphan drug Siklos: the Council of State takes over the decision.

Authors:  Susana Murteira; Emna El Hammi; Mondher Toumi
Journal:  Eur J Health Law       Date:  2014-12

5.  A physical map of the human genome.

Authors:  J D McPherson; M Marra; L Hillier; R H Waterston; A Chinwalla; J Wallis; M Sekhon; K Wylie; E R Mardis; R K Wilson; R Fulton; T A Kucaba; C Wagner-McPherson; W B Barbazuk; S G Gregory; S J Humphray; L French; R S Evans; G Bethel; A Whittaker; J L Holden; O T McCann; A Dunham; C Soderlund; C E Scott; D R Bentley; G Schuler; H C Chen; W Jang; E D Green; J R Idol; V V Maduro; K T Montgomery; E Lee; A Miller; S Emerling; R Gibbs; S Scherer; J H Gorrell; E Sodergren; K Clerc-Blankenburg; P Tabor; S Naylor; D Garcia; P J de Jong; J J Catanese; N Nowak; K Osoegawa; S Qin; L Rowen; A Madan; M Dors; L Hood; B Trask; C Friedman; H Massa; V G Cheung; I R Kirsch; T Reid; R Yonescu; J Weissenbach; T Bruls; R Heilig; E Branscomb; A Olsen; N Doggett; J F Cheng; T Hawkins; R M Myers; J Shang; L Ramirez; J Schmutz; O Velasquez; K Dixon; N E Stone; D R Cox; D Haussler; W J Kent; T Furey; S Rogic; S Kennedy; S Jones; A Rosenthal; G Wen; M Schilhabel; G Gloeckner; G Nyakatura; R Siebert; B Schlegelberger; J Korenberg; X N Chen; A Fujiyama; M Hattori; A Toyoda; T Yada; H S Park; Y Sakaki; N Shimizu; S Asakawa; K Kawasaki; T Sasaki; A Shintani; A Shimizu; K Shibuya; J Kudoh; S Minoshima; J Ramser; P Seranski; C Hoff; A Poustka; R Reinhardt; H Lehrach
Journal:  Nature       Date:  2001-02-15       Impact factor: 49.962

6.  Busting the billion-dollar myth: how to slash the cost of drug development.

Authors:  Amy Maxmen
Journal:  Nature       Date:  2016-08-25       Impact factor: 49.962

7.  Nonprofit biomedical companies.

Authors:  R M Conti; D O Meltzer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2008-08       Impact factor: 6.875

8.  Drug licenses: a new model for pharmaceutical pricing.

Authors:  Dana P Goldman; Anupam B Jena; Tomas Philipson; Eric Sun
Journal:  Health Aff (Millwood)       Date:  2008 Jan-Feb       Impact factor: 6.301

9.  Pricing and reimbursement of orphan drugs: the need for more transparency.

Authors:  Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2011-06-17       Impact factor: 4.123

10.  Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe.

Authors:  Goran Medic; Daria Korchagina; Katherine Eve Young; Mondher Toumi; Maarten Jacobus Postma; Micheline Wille; Michiel Hemels
Journal:  J Mark Access Health Policy       Date:  2017-04-10
View more
  1 in total

1.  Non-profit drug research and development: the case study of Genethon.

Authors:  Szymon Jarosławski; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2018-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.